SCHEMBL3008296

SCHEMBL3008296

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(C(F)(F)F)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
HSD17B10 Q99714 2/20 0.45
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HTR6 P50406 2/20 0.40
HSD11B1 P28845 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3644344 0.97 ALDH1A1 (0.43) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3018135 0.93 ALDH1A1 (0.46) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3005447 0.92 RAB9A (0.45) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3763837 0.91 ALDH1A1 (0.43) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3019810 0.91 HSD17B10 (0.46) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3012814 0.91 MEN1 (0.48) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3013621 0.91 ALDH1A1 (0.48) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3008733 0.90 L3MBTL1 (0.50) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3021657 0.90 ALDH1A1 (0.45) ALDH1A1L3MBTL1MEN1TSHRKMT2A
SCHEMBL3015010 0.89 SMN1; SMN2 (0.40) ALDH1A1L3MBTL1MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885L3MBTL1 1847/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.